Anti-BRCA1 (Breast Cancer 1, Breast cancer 1 early onset, Breast cancer type 1 susceptibility protei

Anti-BRCA1 (Breast Cancer 1, Breast cancer 1 early onset, Breast cancer type 1 susceptibility protei
Item number Size Datasheet Manual SDS Delivery time Quantity Price
B2709-05J.100 100 µl - -

3 - 19 business days*

688.00€
 
BRCA1 (breast and ovarian cancer susceptibility protein 1) is a RING finger protein containing a... more
Product information "Anti-BRCA1 (Breast Cancer 1, Breast cancer 1 early onset, Breast cancer type 1 susceptibility protei"
BRCA1 (breast and ovarian cancer susceptibility protein 1) is a RING finger protein containing a BRCT domain. BRCA1 exists as a heterodimer with 22 possible isoforms. The full length protein has a reported molecular weight of 208kD. BRCA1 localizes to the mitotic spindle microtubules, centriole walls, pericentriolar fibers at centrosomes. Unphosphorylated BRCA1 localizes on chromosomes from metaphase through telophase, phosphorylated BRCA1 resides in inner chromosomal structure, centrosome, cleavage furrow during prophase through telophase, and relocalizes to the perinuclear region when cells are subjected to IR or UV radiation in S phase. BRCA1 acts as a tumor suppressor and can function as a secreted growth inhibitory protein, participate in transcription coupled repair of oxidative DNA damage, X-chromosome inactivation, and can function as a E3 ubiquitin ligase. BRCA1 can be transcriptionally downregulated by Ets-2, Brg-1, and Hmga-1. BRCA1 can be modified by glycosylation, ubiquitination and phosphorylation by CDK4, ATM/ATR, cdk2, and hChk2. The BRCA1 protein has been reported to interact with RNA polymerase II holoenzyme and BARD1. BRCA1 contains at least two nuclear localization signals and is proposed to be a tumor suppressor protein. It is a serine phosphoprotein that undergoes hyperphosphorylation during late G1 and S phases of the cell cycle and is transiently dephosphorylated early after M phase. BRCA1 protein alters in a qualitative and quantitative manner during cell cycle progression. The amount of BRCA1 protein is highest during S phase and remains elevated toward G2 / M, before it declines in early G1 phase. Inherited loss of BRCA1 function confers an increased susceptibility for both breast and ovarian cancer. Cellular Localization: nuclear, Positive Control: U2OS and MCF-7 whole cell lysates , Applications: , Suitable for use in Immunofluorescence, Western Blot and Immunoprecipitation. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot Store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Supplier: United States Biological
Supplier-Nr: B2709-05J

Properties

Application: IF, IP, WB
Antibody Type: Monoclonal
Clone: 8J374
Conjugate: No
Host: Mouse
Species reactivity: human
Immunogen: Human BRCA1 (between residues 1314-1864).
Format: Affinity Purified

Database Information

Handling & Safety

Storage: -20°C
Shipping: +4°C (International: +4°C)
Caution
Our products are for laboratory research use only: Not for administration to humans!
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "Anti-BRCA1 (Breast Cancer 1, Breast cancer 1 early onset, Breast cancer type 1 susceptibility protei"
Write a review
or to review a product.
Viewed